Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000022928
Abstract: Abstract Rationale: Primary leptomeningeal melanoma is an extremely rare disease of the central nervous system. There are no standard treatment protocols with a poor prognosis in very few reported cases. Immunotherapy in primary brain melanoma… read more here.
Keywords: successfully treated; leptomeningeal melanomatosis; inhibitor pembrolizumab; primary leptomeningeal ... See more keywords
A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028613
Abstract: Abstract Rationale: Primary diffuse leptomeningeal melanomatosis (PDLM) is a rare disease that affects melanocytes in the leptomeninges. There is very limited data on the efficacy of immunotherapy in this setting. Patient concerns: A patient (23 years… read more here.
Keywords: whole brain; primary diffuse; patient; diffuse leptomeningeal ... See more keywords
CSF cytology diagnosis of NRAS‐mutated primary leptomeningeal melanomatosis with neurocutaneous melanosis
Sign Up to like & getrecommendations! Published in 2017 at "Cytopathology"
DOI: 10.1111/cyt.12366
Abstract: Primary leptomeningeal melanomatosis (PLM) is an extremely rare diffuse malignant melanocytic neoplasm infiltrating into the subarachnoidal space and superficial brain without a localised mass. It may be found in isolation or in the context of… read more here.
Keywords: diagnosis; neurocutaneous melanosis; leptomeningeal melanomatosis; primary leptomeningeal ... See more keywords